Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

Delayed Quote. Delayed  - 07/25 10:00:00 pm
2.81 USD   -1.40%
07/21 IMMUNOGEN, INC. : Announces Conference Call to Discuss Its Fourth Qu..
06/15 IMMUNOGEN : Announces Pricing of $100 Million Offering of 4.50% Conv..
06/13 IMMUNOGEN : Announces Proposed $100 Million Offering of Convertible ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

FDA Approves Kadcyla, Breast-Cancer Drug from Roche, ImmunoGen

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 05:26pm CEST
   By Jennifer Corbett Dooren 
 

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline PLC's (GSK, GSK.LN) Tykerb. The drugs were administered every three weeks until the disease progressed or patients experienced unmanageable side effects.

The study was designed to measure progression-free survival, which is a measurement of the time from the start of treatment until the disease gets worse or the patient dies, and overall survival, which is a measurement of time from the start of treatment until death.

The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared with 6.4 months in the group receiving Xeloda and Tykerb, a difference considered statistically significant. The median overall survival was 30.9 months in the Kadcyla group and 25.1 months for Xeloda and Tykerb group.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : ImmunoGen, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOGEN, INC.
07/21 IMMUNOGEN, INC. : Announces Conference Call to Discuss Its Fourth Quarter and Fi..
06/30 IMMUNOGEN : Study Results from ImmunoGen, Inc. in the Area of Immunoglobulins Re..
06/20 IMMUNOGEN INC : Entry into a Material Definitive Agreement, Creation of a Direct..
06/16 IMMUNOGEN : Findings from ImmunoGen, Inc. Update Understanding of Enterobacteria..
06/15 IMMUNOGEN : Announces Pricing of $100 Million Offering of 4.50% Convertible Seni..
06/13 IMMUNOGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
06/13 IMMUNOGEN : Announces Proposed $100 Million Offering of Convertible Senior Notes..
05/18 IMMUNOGEN : Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetu..
05/12 IMMUNOGEN : Appoints Mark J. Enyedy as President and Chief Executive Officer
05/12 IMMUNOGEN : Reports Third Quarter Fiscal Year 2016 Financial Results and Provide..
More news
Sector news : Biotechnology & Medical Research - NEC
12:45a GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJCELGENE : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/07 ImmunoGen Oversold Despite Strong Pipeline
06/14 Midday Gainers / Losers
06/14 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/13 ImmunoGen initiates $100M convertible debt offering
05/03 SEATTLE GENETICS : Now Is A Good Time To Buy
Advertisement
Financials ($)
Sales 2016 69,2 M
EBIT 2016 -113 M
Net income 2016 -131 M
Debt 2016 19,2 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 3,81x
EV / Sales 2017 5,77x
Capitalization 245 M
More Financials
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 8,50 $
Spread / Average Target 202%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David B. Johnston Chief Financial Officer & Executive Vice President
Sandra E. Poole Executive Vice President-Technical Operations
Richard J. Gregory Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOGEN, INC.-79.29%245
INCYTE CORPORATION-20.30%16 216
CELLTRION, INC.--.--%10 681
LONZA GROUP AG11.40%9 730
QUINTILES TRANSNATIONA..7.89%8 865
ALKERMES PLC-36.86%7 576
More Results